Spark Investment Management LLC raised its position in Zafgen, Inc. (NASDAQ:ZFGN) by 49.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 282,200 shares of the biopharmaceutical company’s stock after buying an additional 93,500 shares during the period. Spark Investment Management LLC’s holdings in Zafgen were worth $990,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after buying an additional 447,964 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Zafgen during the first quarter worth about $840,000. Dimensional Fund Advisors LP increased its position in Zafgen by 44.7% in the first quarter. Dimensional Fund Advisors LP now owns 443,311 shares of the biopharmaceutical company’s stock worth $2,066,000 after buying an additional 136,849 shares during the last quarter. Candriam Luxembourg S.C.A. increased its position in Zafgen by 97.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 213,000 shares of the biopharmaceutical company’s stock worth $993,000 after buying an additional 105,000 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Zafgen during the second quarter worth about $304,000. Institutional investors own 52.54% of the company’s stock.
Shares of Zafgen, Inc. (NASDAQ:ZFGN) opened at 3.33 on Friday. The firm’s market cap is $91.15 million. Zafgen, Inc. has a 12-month low of $2.89 and a 12-month high of $5.46. The company has a 50 day moving average of $3.51 and a 200-day moving average of $4.09.
Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the company posted ($0.55) earnings per share. Equities research analysts forecast that Zafgen, Inc. will post ($2.23) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/2801645/spark-investment-management-llc-acquires-93500-shares-of-zafgen-inc-nasdaqzfgn.html.
A number of research analysts have recently issued reports on ZFGN shares. Roth Capital started coverage on shares of Zafgen in a research report on Thursday, April 20th. They issued a “buy” rating and a $9.00 price target on the stock. ValuEngine cut shares of Zafgen from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research cut shares of Zafgen from a “buy” rating to a “hold” rating in a report on Saturday, May 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $24.33.
In other news, insider Dennis D. Kim bought 10,000 shares of Zafgen stock in a transaction dated Tuesday, July 11th. The shares were bought at an average price of $3.39 per share, for a total transaction of $33,900.00. Following the purchase, the insider now owns 21,443 shares of the company’s stock, valued at $72,691.77. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 21.20% of the stock is currently owned by insiders.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen, Inc. (NASDAQ:ZFGN).
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.